Global spending on medicines will reach $1.4 trillion in 2020, driven by increased healthcare access in emerging markets and high-priced new drugs for cancer and other diseases, according to a forecast by IMS Health released on Wednesday. That is up from about $1.07 trillion this year, representing a compound annual growth rate of 4 to 7 percent over the next five years, the "Global Medicines Use in 2020" report compiled by IMS Institute for Healthcare Informatics found. Some 225 new drugs will
NAI500 Comments: i. The Chinese government is heavily focused on the health of its citizens as shown by its decision to build 7,500 public hospitals through the private sector over the next decade. ii. China’s health challenges include significantly high rates of smoking, high pollution levels, and a rapidly aging population. iii. Given China’s healthcare challenges, Canadian healthcare developers should target cancer treatment, heart disease treatment, and age related solutions. iv. The cit
South Korean biotech Genexine Inc. licensed out three of its compounds for $100 million to a Chinese drug developer, exploring the Asian market for next-generation long-acting growth hormone treatments. Clinical-stage Genexine (KOSDAQ:095700) signed a licensing and technology transfer agreement with China's Tasgen, a subsidiary of Tasly Pharmaceutical Group Co. Ltd. (SH:600535). Under the deal reached this week, Genexine will grant the China rights for three compounds, GX-H9, GX-G6 and GX-G3, to Tasgen i
Tencent Holdings, China's largest internet services company, led a $200 million series D round in Haodaifu Online, a large mobile healthcare app. Founded in 2006, Haodaifu, which ...
Replicel Life Sciences Inc is a clinical stage bio-pharmaceutical company engaged in developing a...
Imprimis Pharmaceuticals is a specialty pharmaceutical company focused on the development and com...
Diamedica Inc is a development stage biopharmaceutical company. The Company is engaged in the dis...
Gilber Chan, the President of NAI500, presents the latest speech of 2016 investment strategy on Global Chinese Financial Forum - Vancouver Conference 2016: The Top 10 Developments...
China's policymakers still have ammunition to counter the mainland's slowing economy, including supply-side reforms and subsidized housing, HSBC said. In a note released Tu...
Consumer staples and services, health care, software and auto stocks are Henderson Global Investors' top Chinese stock picks for 2016 — but don't get your hopes up for a...
The leaders of the world's largest economies stuck to a goal of lifting their collective output by an extra 2 percent by 2018, even though growth remains uneven and weaker than expect...
The renminbi's status as a global reserve currency may be effectively guaranteed following formal backing by International Monetary Fund (IMF) staff, according to economists, but trad...
, a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that its CEO Simon Allen will ...
is pleased to announce that it will be featured in the inaugural April issue of the new Canadian CANNAINVESTOR Magazine. To view the Company’s feature article in the new Canadian CA...
("RepliCel" or the "Company") is pleased to report compelling safety and clinical data from its phase 1/2 tendon repair study investigating the use of RepliCel...
|Company Name||Symbol||Price||Change||Vol(k)||Day's Range||Contact|
|1||Conatus Pharmaceuticals Inc||NASDAQ:CNAT||5.920||
||2135309||5.01 - 5.99|
||303501||0.25 - 0.28|
||175489||1.05 - 1.15|
||432292||100.36 - 104.90|
|5||Tenax Therapeutics Inc||NASDAQ:TENX||0.541||
||605134||0.5000 - 0.5470|
|6||Imprimis Pharmaceuticals Inc||NASDAQ:IMMY||4.220||
||687652||4.02 - 4.39|
|7||InspireMD Inc||NYSE MKT:NSPR||1.010||
||1721271||0.93 - 1.05|
|8||DelMar Pharmaceuticals Inc||NASDAQ:DMPI||4.310||
||45621||4.17 - 4.55|
|9||AEterna Zentaris Inc||NASDAQ:AEZS||3.050||
||493408||2.95 - 3.25|
|10||Pernix Therapeutics Holdings Inc||NASDAQ:PTX||3.700||
||252899||3.42 - 3.71|
|11||Acasti Pharma Inc||NASDAQ:ACST||1.320||
||1094249||1.31 - 1.65|
||352034||0.95 - 1.03|
|13||Zecotek Photonics Inc||TSXV:ZMS||0.290||
||814376||0.28 - 0.29|
|14||Nymox Pharmaceutical Corp||NASDAQ:NYMX||3.690||
||254798||3.48 - 3.74|
|15||Merus Labs International Inc||TSX:MSL||1.230||
||49988||1.18 - 1.24|